Publications by authors named "Larry Anderson"

Claim this Profile
P
Predictors of Delayed Responses to Teclistamab in Multiple Myeloma After Initial Non-Response.
Rahul Banerjee, Gurbakhash Kaur, Beatrice M Razzo, Andrew J Portuguese, Surbhi Sidana, Larry D Anderson

Am J Hematol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Real-World Safety and Efficacy of Bispecific T-Cell Engager Therapy in Systemic AL Amyloidosis.
Matthew J Rees, Jack Khouri, Ariel F Grajales-Cruz, Saurabh S Zanwar, Utkarsh Goel, Larry D Anderson

Am J Hematol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy for the treatment of plasma cell leukemia.
Gliceida M Galarza Fortuna, Lauren Peres, Elena Nazarenko, Andre De Menezes Silva Corraes, Vanna N Hovanky, Larry D Anderson

Blood Adv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fludarabine Lymphodepletion Exposure is Associated with Toxicities after Idecabtagene-Vicleucel in Relapsed/Refractory Multiple Myeloma: Real-World Experience from the US Myeloma Immunotherapy Consortium.
Karen Sweiss, Charlotte Wagner, Eric Anto, Tom Greene, Ryan Sun, Larry Anderson

Transplant Cell Ther· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium.
Beatrice M Razzo, Shonali Midha, Andrew J Portuguese, Ariel F Grajales-Cruz, Andre De Menezes Silva Corraes, Larry D Anderson

Blood Cancer Discov· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience.
Aimaz Afrough, Danai Dima, Beatrice Razzo, Utkarsh Goel, Aishwarya Sannareddy, Larry D Anderson

Blood Cancer J· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy.
Binod Dhakal, Othman S Akhtar, David Fandrei, Alexandria Jensen, Rahul Banerjee, Larry D Anderson

Blood· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses.
Laahn Foster, Larry D Anderson, Alfred Chung, Chakra P Chaulagain, Erin Pettijohn

Blood Cancer J· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early peripheral blood and bone marrow MRD as prognostic markers in quadruplet-treated multiple myeloma without transplant.
Benjamin A Derman, Jennifer Cooperrider, Anna Pula, Heidi Simmons, Tadeusz Kubicki, Larry D Anderson

Hemasphere· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Secretory Expression and Purification of Respiratory Syncytial Virus G and F Ectodomain in Human Cells.
Ranjini Sankaranarayanan, Binh Ha, Samadhan J Jadhao, Larry J Anderson

Methods Mol Biol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantification of RSV Antibodies in Human Plasma by Enzyme Immunoassays.
Ranjini Sankaranarayanan, Binh Ha, Samadhan J Jadhao, Larry J Anderson

Methods Mol Biol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing Selection of Bridging Therapies Prior to CAR-T Therapy Administration for Multiple Myeloma: Clinical Pearls From an Expert Roundtable.
Sikander Ailawadhi, Larry D Anderson, Binod Dhakal, Leyla Shune, Douglas W Sborov

Clin Lymphoma Myeloma Leuk· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Teclistamab for patients with heavily pretreated relapsed/refractory multiple myeloma and renal impairment.
Danai Dima, Aimaz Afrough, Utkarsh Goel, Ariel F Grajales-Cruz, Jack Khouri, Larry D Anderson

Blood Adv· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma.
Surbhi Sidana, Nausheen Ahmed, Othman Salim Akhtar, Ruta Brazauskas, Temitope Oloyede, Larry D Anderson

Blood· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Viral Etiologies of Acute Respiratory Illness in Older Adults and of Congestive Heart Failure and Chronic Obstructive Pulmonary Disease Exacerbations Requiring Hospitalization During 2 Prepandemic Respiratory Seasons.
Chris Choi, Gabriella Ess, Ashley Tippett, Luis Salazar, Elizabeth Grace Taylor, Larry J Anderson, Evan J Anderson

Open Forum Infect Dis· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of 17q12-q21 Asthma Risk Locus with Clinical Severity of Infant Respiratory Syncytial Virus Infection.
Kedir N Turi, Christopher McKennan, Christian Rosas-Salazar, Tebeb Gebretsedik, Dawn C Newcomb, Larry Anderson

Biomolecules· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors.
Sarah J Shin, Geraldine O'Sullivan Coyne, Shivaani Kummar, Sarah B Miller, Barry C Johnson, Larry Anderson

Clin Cancer Res· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fc-effector functional antibody assays for SARS-CoV-2 variants of concern.
Xuemin Chen, Grace Li, Caroline Ciric, Theda Gibson, Larry J Anderson

Front Immunol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium.
Danai Dima, Mariola A Vazquez-Martinez, James A Davis, Utkarsh Goel, Aimaz Afrough, Larry D Anderson

Blood Cancer J· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma.
Rahul Banerjee, Alicia Richards, Shonali Midha, Aimaz Afrough, Faiz Anwer, Larry D Anderson

Blood Adv· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025.
Shaji K Kumar, Natalie S Callander, Kehinde Adekola, Larry D Anderson, Muhamed Baljevic

J Natl Compr Canc Netw· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium.
Oren Pasvolsky, Danai Dima, Lei Feng, Wenli Dong, Tiffany Richards, Larry D Anderson

Blood Cancer J· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-cell profiling demonstrates the combined effect of wheeze phenotype and infant viral infection on airway epithelial development.
Sergejs Berdnikovs, Dawn C Newcomb, Nana-Fatima Haruna, Kaitlin E McKernan, Shelby N Kuehnle, Larry J Anderson

Sci Adv· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma.
Doris K Hansen, Lauren C Peres, Danai Dima, Alicia Richards, Leyla Shune, Larry D Anderson

J Clin Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysis.
Sharlene Dong, Rahul Banerjee, Adeel M Khan, Mengru Wang, Xiaoliang Wang, Larry D Anderson

Blood Cancer J· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis